We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1603 for:    SUSTAIN 4
Previous Study | Return to List | Next Study

Efficacy and Safety of Semaglutide Once Weekly Versus Insulin Glargine Once Daily as add-on to Metformin With or Without Sulphonylurea in Insulin-naïve Subjects With Type 2 Diabetes (SUSTAIN™ 4)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT02128932
First Posted: May 1, 2014
Last Update Posted: April 28, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Novo Nordisk A/S
  Purpose
This trial is conducted in Africa, North and South America, Asia and Europe. The purpose of the trial is to compare the effect of once-weekly dosing of two dose levels of semaglutide versus insulin glargine once-daily on glycaemic control after 30 weeks of treatment in insulin-naïve subjects with type 2 diabetes.

Condition Intervention Phase
Diabetes Diabetes Mellitus, Type 2 Drug: semaglutide Drug: insulin glargine Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Efficacy and Safety of Semaglutide Once Weekly Versus Insulin Glargine Once Daily as Add on to Metformin With or Without Sulphonylurea in Insulin-naïve Subjects With Type 2 Diabetes

Resource links provided by NLM:


Further study details as provided by Novo Nordisk A/S:

Primary Outcome Measures:
  • Change in HbA1c from baseline [ Time Frame: Week 0, week 30 ]

Secondary Outcome Measures:
  • Change in body weight from baseline [ Time Frame: Week 0, week 30 ]
  • Change in fasting plasma glucose from baseline [ Time Frame: Week 0, week 30 ]
  • Change in systolic and diastolic blood pressure from baseline [ Time Frame: Week 0, week 30 ]
  • Change in patient reported outcome (PRO) questionnaire SF-36v2™ from baseline [ Time Frame: Week 0, week 30 ]
  • Change in patient reported outcome (PRO) questionnaire DTSQs (diabetes treatment satisfaction questionnaire) from baseline [ Time Frame: Week 0, week 30 ]
  • Subjects who achieve HbA1c equal to or below 6.5% (48 mmol/mol) American Association of Clinical Endocrinologists (AACE) target: (yes/no) [ Time Frame: After 30 weeks treatment ]

Enrollment: 1089
Actual Study Start Date: August 4, 2014
Study Completion Date: September 3, 2015
Primary Completion Date: September 3, 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Semaglutide 0.5 mg/week Drug: semaglutide
Injected subcutaneously (under the skin) once weekly. Following 4 doses (4 weeks) of 0.25 mg semaglutide weekly subjects will receive 0.5 mg semaglutide weekly for 26 weeks.
Experimental: Semaglutide 1.0 mg/week Drug: semaglutide
Injected subcutaneously (under the skin) once weekly. Following 4 doses (4 weeks) of 0.25 mg semaglutide weekly subjects will receive 0.5 mg semaglutide weekly for 26 weeks.
Active Comparator: Insulin glargine Drug: insulin glargine
Injected subcutaneously (under the skin) once daily. Subjects will start on 10 IU once daily and the dose will be adjusted according to fasting plasma glucose.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male or female, 18 years or older at the time of signing informed consent
  • Insulin-naïve subjects diagnosed with type 2 diabetes and on stable diabetes treatment with metformin or metformin and SU (metformin 1500 mg or higher or maximum tolerated dose and SU half of maximum allowed dose according to national label or higher) for at least 90 days before screening. Stable is defined as unchanged medication and unchanged dose
  • HbA1c 7.0 - 10.0% (53 - 86 mmol/mol) both inclusive

Exclusion Criteria:

  • Female who is pregnant, breast-feeding or intends to become pregnant or of childbearing potential not using adequate contraceptive method (adequate contraceptive measures as required by local regulation or practice) throughout the trial including the 5 week follow-up period
  • Any disorder which, in the opinion of the Investigator might jeopardise subject's safety or compliance with the protocol
  • Treatment with any glucose lowering agent(s) other than stated in the inclusion criteria in a period of 90 days before screening. An exception is short-term treatment (7 days or less in total) with insulin in connection with intercurrent illness
  • History of chronic or idiopathic acute pancreatitis
  • Screening calcitonin value greater than or equal to 50 ng/L
  • Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome 2
  • Severe renal impairment defined as estimated glomerular filtration rate (eGFR) less than 30 mL/min/1.73 m^2 per modification of diet in renal disease (MDRD) formula (4 variable version)
  • Acute coronary or cerebrovascular event within 90 days before randomisation
  • Heart failure, New York Heart Association Class IV
  • Known proliferative retinopathy or maculopathy requiring acute treatment according to the opinion of the investigator
  • Diagnosis of malignant neoplasm in the previous 5 years (except basal cell skin cancer or squamous cell skin cancer)
  • Mental inability, unwillingness or language barrier precluding adequate understanding of or compliance with study procedures
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02128932


  Hide Study Locations
Locations
United States, Alabama
Novo Nordisk Investigational Site
Birmingham, Alabama, United States, 35216
Novo Nordisk Investigational Site
Ozark, Alabama, United States, 36360
Novo Nordisk Investigational Site
Tuscumbia, Alabama, United States, 35674
United States, Arizona
Novo Nordisk Investigational Site
Gilbert, Arizona, United States, 85295
Novo Nordisk Investigational Site
Phoenix, Arizona, United States, 85018
Novo Nordisk Investigational Site
Phoenix, Arizona, United States, 85032
United States, California
Novo Nordisk Investigational Site
Anaheim, California, United States, 92801
Novo Nordisk Investigational Site
Carmichael, California, United States, 95608
Novo Nordisk Investigational Site
Chula Vista, California, United States, 91911
Novo Nordisk Investigational Site
Elk Grove, California, United States, 95758
Novo Nordisk Investigational Site
Inglewood, California, United States, 90301
Novo Nordisk Investigational Site
La Mesa, California, United States, 91942
Novo Nordisk Investigational Site
Long Beach, California, United States, 90807
Novo Nordisk Investigational Site
Los Angeles, California, United States, 90057
Novo Nordisk Investigational Site
Oceanside, California, United States, 92056
Novo Nordisk Investigational Site
Orange, California, United States, 92868-2863
Novo Nordisk Investigational Site
Pomona, California, United States, 91767-3008
Novo Nordisk Investigational Site
Rialto, California, United States, 92376
Novo Nordisk Investigational Site
Rolling Hills Estates, California, United States, 90274
Novo Nordisk Investigational Site
Roseville, California, United States, 95661
Novo Nordisk Investigational Site
San Diego, California, United States, 92111
Novo Nordisk Investigational Site
San Mateo, California, United States, 94401
Novo Nordisk Investigational Site
Sherman Oaks, California, United States, 91403
Novo Nordisk Investigational Site
Spring Valley, California, United States, 91978
Novo Nordisk Investigational Site
Tustin, California, United States, 92780
Novo Nordisk Investigational Site
Walnut Creek, California, United States, 94598
United States, Colorado
Novo Nordisk Investigational Site
Colorado Springs, Colorado, United States, 80909
Novo Nordisk Investigational Site
Denver, Colorado, United States, 80220
Novo Nordisk Investigational Site
Denver, Colorado, United States, 80239-3133
United States, Florida
Novo Nordisk Investigational Site
Brooksville, Florida, United States, 34601
Novo Nordisk Investigational Site
Clearwater, Florida, United States, 33761
Novo Nordisk Investigational Site
Cooper City, Florida, United States, 33024
Novo Nordisk Investigational Site
Hialeah, Florida, United States, 33012
Novo Nordisk Investigational Site
Jacksonville, Florida, United States, 32205
Novo Nordisk Investigational Site
Jacksonville, Florida, United States, 32216
Novo Nordisk Investigational Site
Jacksonville, Florida, United States, 32256
Novo Nordisk Investigational Site
Kissimmee, Florida, United States, 34741
Novo Nordisk Investigational Site
Lakeland, Florida, United States, 33805
Novo Nordisk Investigational Site
Miami Lakes, Florida, United States, 33016
Novo Nordisk Investigational Site
Miami, Florida, United States, 33135
Novo Nordisk Investigational Site
Miami, Florida, United States, 33156
Novo Nordisk Investigational Site
Winter Haven, Florida, United States, 33880
Novo Nordisk Investigational Site
Winter Park, Florida, United States, 32789
United States, Georgia
Novo Nordisk Investigational Site
Conyers, Georgia, United States, 30013
Novo Nordisk Investigational Site
Johns Creek, Georgia, United States, 30097
Novo Nordisk Investigational Site
Marietta, Georgia, United States, 30060
Novo Nordisk Investigational Site
Norcross, Georgia, United States, 30092
Novo Nordisk Investigational Site
Roswell, Georgia, United States, 30076
United States, Idaho
Novo Nordisk Investigational Site
Meridian, Idaho, United States, 83646
United States, Illinois
Novo Nordisk Investigational Site
Chicago, Illinois, United States, 60611
Novo Nordisk Investigational Site
Gurnee, Illinois, United States, 60031
Novo Nordisk Investigational Site
Peoria, Illinois, United States, 61602
United States, Indiana
Novo Nordisk Investigational Site
Avon, Indiana, United States, 46123
Novo Nordisk Investigational Site
Indianapolis, Indiana, United States, 46254
United States, Iowa
Novo Nordisk Investigational Site
Council Bluffs, Iowa, United States, 51501
United States, Kansas
Novo Nordisk Investigational Site
Park City, Kansas, United States, 67219
United States, Kentucky
Novo Nordisk Investigational Site
Crestview Hills, Kentucky, United States, 41017-3464
Novo Nordisk Investigational Site
Lexington, Kentucky, United States, 40503
Novo Nordisk Investigational Site
Madisonville, Kentucky, United States, 42431
Novo Nordisk Investigational Site
Paducah, Kentucky, United States, 42003
United States, Louisiana
Novo Nordisk Investigational Site
Lake Charles, Louisiana, United States, 70601
Novo Nordisk Investigational Site
Metairie, Louisiana, United States, 70002
Novo Nordisk Investigational Site
Natchitoches, Louisiana, United States, 71457-5881
Novo Nordisk Investigational Site
Shreveport, Louisiana, United States, 71107
United States, Maryland
Novo Nordisk Investigational Site
Hyattsville, Maryland, United States, 20782
United States, Michigan
Novo Nordisk Investigational Site
Buckley, Michigan, United States, 49620
Novo Nordisk Investigational Site
Flint, Michigan, United States, 48504
Novo Nordisk Investigational Site
Sterling Heights, Michigan, United States, 48310-3503
Novo Nordisk Investigational Site
Troy, Michigan, United States, 48098
United States, Missouri
Novo Nordisk Investigational Site
Saint Louis, Missouri, United States, 63128
Novo Nordisk Investigational Site
Saint Louis, Missouri, United States, 63141
United States, Montana
Novo Nordisk Investigational Site
Butte, Montana, United States, 59701
United States, Nevada
Novo Nordisk Investigational Site
Las Vegas, Nevada, United States, 89109
Novo Nordisk Investigational Site
Las Vegas, Nevada, United States, 89119
Novo Nordisk Investigational Site
Las Vegas, Nevada, United States, 89120
United States, New Jersey
Novo Nordisk Investigational Site
Berlin, New Jersey, United States, 08009
Novo Nordisk Investigational Site
Toms River, New Jersey, United States, 08755-8050
Novo Nordisk Investigational Site
Trenton, New Jersey, United States, 08611
United States, New Mexico
Novo Nordisk Investigational Site
Albuquerque, New Mexico, United States, 87108
United States, New York
Novo Nordisk Investigational Site
Brooklyn, New York, United States, 11229
Novo Nordisk Investigational Site
New Windsor, New York, United States, 12553
Novo Nordisk Investigational Site
West Seneca, New York, United States, 14224
United States, North Carolina
Novo Nordisk Investigational Site
Greensboro, North Carolina, United States, 27408
Novo Nordisk Investigational Site
Morehead City, North Carolina, United States, 28557
Novo Nordisk Investigational Site
Morganton, North Carolina, United States, 28655
Novo Nordisk Investigational Site
Shelby, North Carolina, United States, 28150
Novo Nordisk Investigational Site
Statesville, North Carolina, United States, 28625
Novo Nordisk Investigational Site
Wilmington, North Carolina, United States, 28401
United States, North Dakota
Novo Nordisk Investigational Site
Fargo, North Dakota, United States, 58103
United States, Ohio
Novo Nordisk Investigational Site
Canal Fulton, Ohio, United States, 44614
Novo Nordisk Investigational Site
Carlisle, Ohio, United States, 45005
Novo Nordisk Investigational Site
Cincinnati, Ohio, United States, 45219
Novo Nordisk Investigational Site
Cincinnati, Ohio, United States, 45227
Novo Nordisk Investigational Site
Cincinnati, Ohio, United States, 45242
Novo Nordisk Investigational Site
Cleveland, Ohio, United States, 44122
Novo Nordisk Investigational Site
Kettering, Ohio, United States, 45429
Novo Nordisk Investigational Site
Mason, Ohio, United States, 45040-6815
Novo Nordisk Investigational Site
Maumee, Ohio, United States, 43537
Novo Nordisk Investigational Site
Toledo, Ohio, United States, 43623
United States, Oregon
Novo Nordisk Investigational Site
Corvallis, Oregon, United States, 97330-3737
United States, Pennsylvania
Novo Nordisk Investigational Site
Altoona, Pennsylvania, United States, 16602
Novo Nordisk Investigational Site
Beaver, Pennsylvania, United States, 15009
Novo Nordisk Investigational Site
Clairton, Pennsylvania, United States, 15025-3730
Novo Nordisk Investigational Site
Jersey Shore, Pennsylvania, United States, 17740
Novo Nordisk Investigational Site
Lansdale, Pennsylvania, United States, 19446-1002
Novo Nordisk Investigational Site
Philadelphia, Pennsylvania, United States, 19114
United States, South Carolina
Novo Nordisk Investigational Site
Gaffney, South Carolina, United States, 29341
Novo Nordisk Investigational Site
Murrells Inlet, South Carolina, United States, 29576
United States, South Dakota
Novo Nordisk Investigational Site
Rapid City, South Dakota, United States, 57701
United States, Tennessee
Novo Nordisk Investigational Site
Chattanooga, Tennessee, United States, 37404
Novo Nordisk Investigational Site
Knoxville, Tennessee, United States, 37912
United States, Texas
Novo Nordisk Investigational Site
Amarillo, Texas, United States, 79106
Novo Nordisk Investigational Site
Austin, Texas, United States, 78756
Novo Nordisk Investigational Site
Dallas, Texas, United States, 75251
Novo Nordisk Investigational Site
Fort Worth, Texas, United States, 76117
Novo Nordisk Investigational Site
Houston, Texas, United States, 77055
Novo Nordisk Investigational Site
Houston, Texas, United States, 77058
Novo Nordisk Investigational Site
Houston, Texas, United States, 77070
Novo Nordisk Investigational Site
Houston, Texas, United States, 77074
Novo Nordisk Investigational Site
Humble, Texas, United States, 77338
Novo Nordisk Investigational Site
Hurst, Texas, United States, 76054
Novo Nordisk Investigational Site
Irving, Texas, United States, 75061-2210
Novo Nordisk Investigational Site
Longview, Texas, United States, 75605
Novo Nordisk Investigational Site
Marshall, Texas, United States, 75670
Novo Nordisk Investigational Site
Plano, Texas, United States, 75075
Novo Nordisk Investigational Site
San Antonio, Texas, United States, 78209
Novo Nordisk Investigational Site
San Antonio, Texas, United States, 78229
United States, Utah
Novo Nordisk Investigational Site
Saint George, Utah, United States, 84790
Novo Nordisk Investigational Site
Salt Lake City, Utah, United States, 84107
United States, Virginia
Novo Nordisk Investigational Site
Arlington, Virginia, United States, 22206
Novo Nordisk Investigational Site
Winchester, Virginia, United States, 22601
United States, Washington
Novo Nordisk Investigational Site
Olympia, Washington, United States, 98502
Novo Nordisk Investigational Site
Renton, Washington, United States, 98057
Novo Nordisk Investigational Site
Wenatchee, Washington, United States, 98801-2028
United States, Wisconsin
Novo Nordisk Investigational Site
Kenosha, Wisconsin, United States, 53142
Argentina
Novo Nordisk Investigational Site
Buenos Aires, Argentina, C1425AGC
Novo Nordisk Investigational Site
Caba, Argentina, C1119ACN
Novo Nordisk Investigational Site
Capital Federal, Argentina, C1056ABJ
Novo Nordisk Investigational Site
Godoy Cruz, Argentina, M5501ARP
Croatia
Novo Nordisk Investigational Site
Cakovec, Croatia, 40000
Novo Nordisk Investigational Site
Karlovac, Croatia, 47000
Novo Nordisk Investigational Site
Krapinske Toplice, Croatia, 49217
Novo Nordisk Investigational Site
Zagreb, Croatia, 10 000
France
Novo Nordisk Investigational Site
Bobigny, France, 93009
Novo Nordisk Investigational Site
Bois-Guillaume, France, 76320
Novo Nordisk Investigational Site
Bourgoin-jallieu, France, 38302
Novo Nordisk Investigational Site
LA ROCHE-sur-YON cedex 9, France, 85295
Novo Nordisk Investigational Site
Le Creusot, France, 71200
Novo Nordisk Investigational Site
MARSEILLE cedex 08, France, 13285
Novo Nordisk Investigational Site
MARSEILLE Cédex 05, France, 13385
Novo Nordisk Investigational Site
Nanterre, France, 92014
Novo Nordisk Investigational Site
Narbonne, France, 11108
Novo Nordisk Investigational Site
NICE cedex 3, France, 06202
Novo Nordisk Investigational Site
Paris, France, 75014
Novo Nordisk Investigational Site
Pierre-Bénite, France, 69495
Novo Nordisk Investigational Site
Pointe à Pitre, France, 97159
Novo Nordisk Investigational Site
Rang-du-fliers, France, 62180
Novo Nordisk Investigational Site
Saint Herblain, France, 44800
Novo Nordisk Investigational Site
Saint Nazaire, France, 44600
Novo Nordisk Investigational Site
Strasbourg, France, 67098
Novo Nordisk Investigational Site
Trinité - La Martinique, France, 97235
Novo Nordisk Investigational Site
Venissieux, France, 69200
Germany
Novo Nordisk Investigational Site
Berlin, Germany, 10409
Novo Nordisk Investigational Site
Essen, Germany, 45276
Novo Nordisk Investigational Site
Jerichow, Germany, 39319
Novo Nordisk Investigational Site
Lampertheim, Germany, 68623
Novo Nordisk Investigational Site
Ludwigshafen, Germany, 67059
Novo Nordisk Investigational Site
Münster, Germany, 48145
Novo Nordisk Investigational Site
Neuwied, Germany, 56564
Novo Nordisk Investigational Site
Rehlingen-Siersburg, Germany, 66780
Novo Nordisk Investigational Site
Rostock, Germany, 18057
Novo Nordisk Investigational Site
St. Ingbert, Germany, 66386
Novo Nordisk Investigational Site
Stuttgart, Germany, 70378
Novo Nordisk Investigational Site
Wangen, Germany, 88239
India
Novo Nordisk Investigational Site
Ahmedabad, Gujarat, India, 380006
Novo Nordisk Investigational Site
Ahmedabad, Gujarat, India, 380007
Novo Nordisk Investigational Site
Bangalore, Karnataka, India, 560092
Novo Nordisk Investigational Site
Mysore, Karnataka, India, 570001
Novo Nordisk Investigational Site
Mysore, Karnataka, India, 570004
Novo Nordisk Investigational Site
Indore, Madhya Pradesh, India, 452010
Novo Nordisk Investigational Site
Mumbai, Maharashtra, India, 400008
Novo Nordisk Investigational Site
Mumbai, Maharashtra, India, 400010
Novo Nordisk Investigational Site
Mumbai, Maharashtra, India, 400012
Novo Nordisk Investigational Site
Mumbai, Maharashtra, India, 400022
Novo Nordisk Investigational Site
New Dehli, New Delhi, India, 110029
Novo Nordisk Investigational Site
Chennai, Tamil Nadu, India, 600031
Novo Nordisk Investigational Site
Kolkata, West Bengal, India, 700107
Novo Nordisk Investigational Site
Kolkata, India, 700026
Novo Nordisk Investigational Site
New Delhi, India, 110001
Macedonia, The Former Yugoslav Republic of
Novo Nordisk Investigational Site
Skopje, Macedonia, The Former Yugoslav Republic of, 1000
Novo Nordisk Investigational Site
Tetovo, Macedonia, The Former Yugoslav Republic of, 1220
Mexico
Novo Nordisk Investigational Site
Guadalajara, Jalisco, Mexico, 44150
Novo Nordisk Investigational Site
Distrito Federal, México, D.F., Mexico, 14000
Novo Nordisk Investigational Site
México D.F., México, D.F., Mexico, 11550
Novo Nordisk Investigational Site
Aguascalientes, Mexico, 20230
Netherlands
Novo Nordisk Investigational Site
Amsterdam, Netherlands, 1105 AZ
Novo Nordisk Investigational Site
Hoofddorp, Netherlands, 2134 TM
Novo Nordisk Investigational Site
Rotterdam, Netherlands, 3039 BD
Puerto Rico
Novo Nordisk Investigational Site
Ponce, Puerto Rico, 00717
Romania
Novo Nordisk Investigational Site
Pitesti, Arges, Romania, 110084
Novo Nordisk Investigational Site
Oradea, Bihor, Romania, 410469
Novo Nordisk Investigational Site
Cluj Napoca, Cluj, Romania, 400006
Novo Nordisk Investigational Site
Bucharest, Romania, 011234
Novo Nordisk Investigational Site
Iasi, Romania, 700469
Slovakia
Novo Nordisk Investigational Site
Kosice, Slovakia, 04011
Novo Nordisk Investigational Site
Moldava nad Bodvou, Slovakia, 045 01
Novo Nordisk Investigational Site
Piestany, Slovakia, 92101
Novo Nordisk Investigational Site
Puchov, Slovakia, 02001
Novo Nordisk Investigational Site
Trencin, Slovakia, 91101
Slovenia
Novo Nordisk Investigational Site
Koper, Slovenia, SI-6000
Novo Nordisk Investigational Site
Ljubljana, Slovenia, 1525
Novo Nordisk Investigational Site
Novo mesto, Slovenia, 8000
South Africa
Novo Nordisk Investigational Site
Johannesburg, Gauteng, South Africa, 1829
Novo Nordisk Investigational Site
Johannesburg, Gauteng, South Africa, 2001
Novo Nordisk Investigational Site
Pretoria, Gauteng, South Africa, 0183
Novo Nordisk Investigational Site
Durban, KwaZulu-Natal, South Africa, 4001
Novo Nordisk Investigational Site
Cape Town, Western Cape, South Africa, 7450
United Kingdom
Novo Nordisk Investigational Site
Basingstoke, United Kingdom, RG24 9GT
Novo Nordisk Investigational Site
Bristol, United Kingdom, BS10 5NB
Novo Nordisk Investigational Site
Harrogate, North Yorkshire, United Kingdom, HG2 7SX
Novo Nordisk Investigational Site
Haxey, United Kingdom, DN9 2HY
Novo Nordisk Investigational Site
Hull, United Kingdom, HU3 2RW
Novo Nordisk Investigational Site
Ipswich, United Kingdom, IP4 5PD
Novo Nordisk Investigational Site
Northwood, United Kingdom, HA6 2RN
Novo Nordisk Investigational Site
Plymouth, United Kingdom, PL6 8BQ
Novo Nordisk Investigational Site
Salford, United Kingdom, M6 8HD
Novo Nordisk Investigational Site
Sidcup, United Kingdom, DA14 6LT
Novo Nordisk Investigational Site
Soham, United Kingdom, CB7 5JD
Novo Nordisk Investigational Site
Swansea, United Kingdom, SA2 8PP
Novo Nordisk Investigational Site
Taunton, United Kingdom, TA1 5DA
Sponsors and Collaborators
Novo Nordisk A/S
Investigators
Study Director: Global Clinical Registry (GCR, 1452) Novo Nordisk A/S
  More Information

Additional Information:
Publications:
Responsible Party: Novo Nordisk A/S
ClinicalTrials.gov Identifier: NCT02128932     History of Changes
Other Study ID Numbers: NN9535-3625
2013-004392-12 ( EudraCT Number )
U1111-1146-0211 ( Other Identifier: WHO )
NL47781.018.14 ( Registry Identifier: National Registry in The Netherlands )
First Submitted: April 24, 2014
First Posted: May 1, 2014
Last Update Posted: April 28, 2017
Last Verified: April 2017

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Insulin, Globin Zinc
Insulin
Metformin
Insulin Glargine
Hypoglycemic Agents
Physiological Effects of Drugs